(19)
(11) EP 2 944 310 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
09.03.2016 Bulletin 2016/10

(88) Date of publication A3:
18.11.2015 Bulletin 2015/47

(43) Date of publication:
18.11.2015 Bulletin 2015/47

(21) Application number: 14168742.6

(22) Date of filing: 16.05.2014
(51) International Patent Classification (IPC): 
A61K 31/423(2006.01)
 A61P 11/00(2006.01)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(71) Applicants:
  • Mifcare
    75014 Paris (FR)
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
    75654 Paris Cedex 13 (FR)

(72) Inventors:
  • GUIGNABERT, Christophe
    94110 Arcueil (FR)
  • LE HIRESS, Morane
    94700 Maisons-Alfort (FR)
  • TU, Ly
    94200 Ivry-sur-Seine (FR)
  • JALCE, Gaël
    91240 Saint-Michel-sur-Orge (FR)
  • AKAGAH, Bernardin
    91300 Massy (FR)

(74) Representative: Icosa 
83 avenue Denfert-Rochereau
75014 Paris
75014 Paris (FR)

   


(54) MIF inhibitors for the acute or chronic treatment of pulmonary hypertension


(57) The present invention relates to the use of compounds of general formula I:

and pharmaceutically acceptable enantiomers, salts or solvates thereof, for treating pulmonary hypertension in a subject.